GNCA Stock Recent News Genocea Biosciences Inc. (GNCA) 8.68 11/09/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genocea Biosciences Inc. (GNCA) 8.68 $GNCA

Genocea Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 7:00AM CST
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the third quarter ended September 30, 2014.
GNCA: 8.68 (-0.16)

Genocea Profiles T cell Responses to Identify Antigens Associated with Malaria Episodes
Business Wire - Wed Nov 05, 11:01AM CST
Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today presented study results identifying a cluster of antigens that may be a biomarker of disease. The findings, generated using Genocea's proprietary ATLAS(TM) antigen discovery platform, revealed that malaria leaves a lasting imprint on the immune system. Genocea researchers found evidence that this T cell immunological memory can be detected many years after the previous clinical episode of malaria. The study was presented at the 63rd Annual Meeting of the American Society of Tropical Medicine and Hygiene in New Orleans, LA.
GNCA: 8.68 (-0.16)

Genocea to Announce Third Quarter 2014 Financial Results on November 6, 2014
Business Wire - Thu Oct 30, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on November 6, 2014 at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2014. The presentation, hosted by Genocea President and Chief Executive Officer Chip Clark and Chief Financial Officer Jonathan Poole, will provide an update on the company's recent progress and upcoming milestones.
GNCA: 8.68 (-0.16)

Genocea Up on Positive GEN-003 Data for Genital Herpes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 1:57PM CDT
Genocea Biosciences, Inc. (GNCA) announced data from a phase I/IIa study on its T cell-enabled immunotherapy candidate, GEN-003.
LCI: 50.17 (-0.82), NVAX: 4.95 (-0.20), AMPE: 3.82 (+0.12), GNCA: 8.68 (-0.16)

Genocea Presents Complete Phase 1/2a Data for HSV-2 Immunotherapy at IDWeek
Business Wire - Wed Oct 08, 8:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies against serious infectious diseases, announced today the presentation of final data from the Phase 1/2a study of GEN-003, the company's immunotherapy candidate for treatment of genital herpes. The oral presentation, titled "Therapeutic HSV-2 Vaccine (GEN-003) Results in Durable Reduction in Genital Lesions at 1 Year ", will be given on Saturday, Oct. 11 at IDWeek 2014(TM) in Philadelphia.
GNCA: 8.68 (-0.16)

Genocea wins USD1.2m grant for malaria vaccine discovery
M2 - Wed Sep 24, 6:11AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) disclosed on Tuesday that it has received a USD1.2m grant for the identification of protective T cell antigens for malaria vaccines.
GNCA: 8.68 (-0.16)

Genocea Announces $1.2 Million Grant for Malaria Vaccine Discovery
Business Wire - Tue Sep 23, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the receipt of a $1.2 million grant from the Bill & Melinda Gates Foundation for the identification of protective T cell antigens for malaria vaccines.
GNCA: 8.68 (-0.16)

Genocea to Present at the 21st Annual NewsMakers in the Biotech Industry Conference
Business Wire - Fri Sep 19, 8:00AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the BioCentury 21st Annual NewsMakers in the Biotech Industry Conference. The presentation is scheduled for Friday, September 26, 2014 at 10:30 a.m. ET at the Millennium Broadway Hotel & Conference Center in New York, NY.
GNCA: 8.68 (-0.16)

Virology Publishes Genocea HSV-2 Antigen Discovery Paper
Business Wire - Tue Sep 16, 8:02AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that the peer-reviewed journal Virology has published a paper describing how Genocea used it's ATLAS(TM) platform to identify the herpes simplex virus 2 (HSV-2) antigens for its GEN-003 clinical program. The paper, titled "Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors," positively identified multiple viral antigens that are associated with naturally-induced protective CD4+ and CD8+ T cell responses, presenting possible targets for the development of new immunotherapies and prophylactic vaccines.
GNCA: 8.68 (-0.16)

Genocea reports launch of Phase 2a trial for universal pneumococcal vaccine candidate GEN-004
M2 - Fri Sep 12, 7:58AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) announced on Thursday that it has started its Phase 2a trial of its universal vaccine candidate against pneumococcus, GEN-004.
GNCA: 8.68 (-0.16)

Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate
Business Wire - Thu Sep 11, 1:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company's universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults.
GNCA: 8.68 (-0.16)

Genocea Appoints Kenneth Bate to its Board of Directors
Business Wire - Thu Sep 11, 11:30AM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Kenneth Bate has joined the company's board of directors. Mr. Bate will also serve as chairman of the company's Compensation committee and a member of the Audit committee.
GNCA: 8.68 (-0.16)

Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC
Business Wire - Sat Sep 06, 3:00PM CDT
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today presented data from a Phase 1 study of GEN-004, an investigational vaccine designed to prevent disease caused by all serotypes of pneumococcus (Streptococcus pneumoniae) The poster (G-291), titled "Safety and Immunogenicity of a Novel Lipidated Protein Subunit Streptococcus Pneumoniae vaccine," was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
GNCA: 8.68 (-0.16)

HSV-2 Vaccine in Development: CBCD Congratulates Genocea Biosciences (GNCA)
PRWeb - Sun Aug 17, 1:46AM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
GNCA: 8.68 (-0.16)

Genocea Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported recent corporate highlights and its financial results for the second quarter ended June 30, 2014.
GNCA: 8.68 (-0.16)

Genocea to Announce Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on August 6, 2014 at 9:00 a.m. ET to discuss financial results for the quarter ended June 30, 2014. The presentation, hosted by Genocea president and chief executive officer Chip Clark and chief financial officer Jonathan Poole, will also provide an update on the company's recent progress and upcoming milestones.
GNCA: 8.68 (-0.16)

Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects
Business Wire - Tue Jul 22, 7:02AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company's investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment. The data were presented at the 39th Annual International Herpesvirus Workshop, being held July 19-23, 2014 in Kobe, Japan.
GNCA: 8.68 (-0.16)

Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy
Business Wire - Mon Jul 21, 7:01AM CDT
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company's immunotherapy candidate against herpes simplex-type 2 (HSV-2).
GNCA: 8.68 (-0.16)

Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
SGYP: 3.16 (+0.18), BCRX: 10.46 (+0.14), OHRP: 7.07 (-0.07), GNCA: 8.68 (-0.16)

Genocea Biosciences decides not to pursue public offering due to market conditions
M2 - Thu Jul 17, 5:34AM CDT
Biopharmaceutical company Genocea Biosciences (NasdaqGM:GNCA) said on Wednesday that it has elected not to proceed with its plans to pursue its public offering of 3,400,000 shares of its common stock.
GNCA: 8.68 (-0.16)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 111

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 95

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 104

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 210

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 92

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 58

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 152

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 135

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 55

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading

Top 5 Most Recently Viewed Articles

Main Street Capital Reports Impressive Q2 2025 Financials

Updated Category News Views 326

Main Street's Second Quarter 2025 Financial Performance Main Street Capital Corporation (NYSE: MAIN) recently disclosed its remarkable financial results for the second quarter of 2025. The company reported a net investment income of $88.2 million, which translates to approximately $0.99 per share. Additionally, the distributable net investment income stood at $94.3...

Continue Reading
argenx's Q1 2025 Growth: VYVGART Performance Shines Brightly

Updated Category News Views 463

Q1 2025 Financial Results Unveiled by argenx argenx SE, listed on both Nasdaq and Euronext as ARGX, is making waves in the biotech industry with its recent announcement of first-quarter financial results and a comprehensive business update. CEO Tim Van Hauwermeiren expressed enthusiasm regarding the company's trajectory, focusing on their ambitious "Vision 2030"—a...

Continue Reading
Pennsylvania's Resilient Housing Market: An Overview of Trends

Updated Category News Views 135

Pennsylvania Housing Market Shows Notable Resilience The latest data on the housing market in Pennsylvania highlights an encouraging trend, as home prices have experienced a remarkable increase of 6.5% over the past year. This consistent appreciation indicates a vigorous market, even in the face of fluctuating economic conditions. Median Home Prices Reach New Heights In...

Continue Reading
Yum China's Strategy Bolstered by Pizza Hut Buy

Updated Category News Views 129

Yum China's Bold Step Forward Here's a twist in the fast-food market worth chewing on: Yum China has wrapped up its $1.2 billion acquisition of the Pizza Hut brand in Mainland China from Yum! Brands. It's like snagging the keys to a long-coveted car after being the chauffeur for decades. Strategic Flexibility and Margin Growth What's at play? Well, Joey Wat, CEO of Yum...

Continue Reading
Insightful Overview of NCC Group plc's Recent Trading Activity

Updated Category News Views 88

Understanding Recent Trading Activities of NCC Group plc In the fast-paced world of finance, keeping an eye on trading activities can offer invaluable insights. One company that has recently been under the spotlight is NCC Group plc. The trading revelations come from public disclosures made under Rule 8.5, indicating vital movements in their securities. Key Information...

Continue Reading